Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00431756 · ClinicalTrials.gov registry record

Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus

A clinical trial of Gastroesophageal Reflux and Barrett Esophagus, sponsored by Johns Hopkins University.

Active
Registry status
600
Enrollment target
1
Study location

NCT00431756: Active study of Gastroesophageal Reflux and Barrett Esophagus, sponsored by Johns Hopkins University.

NCT00431756 is a study of Gastroesophageal Reflux and Barrett Esophagus that is active but no longer recruiting, run by Johns Hopkins University. The registered enrollment target is 600 participants, below the 2,868-participant average among 33 other Gastroesophageal Reflux trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00431756, a study of Gastroesophageal Reflux and Barrett Esophagus, is active but no longer recruiting, sponsored by Johns Hopkins University.

ACTIVE NOT RECRUITING
Registry status
600 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine if there are any early changes in DNA markers of blood and esophageal tissue in people with gastric reflux, Barrett's esophagus or esophageal cancer that can warn of a progression to esophageal cancer.

Primary Outcome

To see if changes in certain areas of DNA can predict risk for esophageal cancer

Study Locations (1)

Maryland

  • Johns Hopkins Hospital - Baltimore

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2002-05-01
Est. Completion 2026-06-01
Johns Hopkins University

1,448 total trials

What the registry record for NCT00431756 still lists

NCT00431756 is an observational study that tracks outcomes without assigning an intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, below the 2,868-participant average among 33 other Gastroesophageal Reflux trials with a reported enrollment target (79% lower).

The record links to 3 conditions, with Gastroesophageal Reflux appearing as the primary indexed condition, and to 0 interventions.

NCT00431756 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT00431756 about?

NCT00431756 is a clinical study titled "Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus". The purpose of this study is to determine if there are any early changes in DNA markers of blood and esophageal tissue in people with gastric reflux, Barrett's esophagus or esophageal cancer that can warn of a progression to esophageal cancer.

What is the current status of trial NCT00431756?

This trial is currently active not recruiting. The enrollment target is 600 participants. The study started on 2002-05-01. Estimated completion is 2026-06-01.

What conditions does trial NCT00431756 study?

This clinical trial studies the following conditions: Gastroesophageal Reflux, Barrett Esophagus, Esophageal Neoplasm.

Who is sponsoring clinical trial NCT00431756?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00431756 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Gastroesophageal Reflux

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00431756's enrollment target sits among peer trials

600 3rd of 33 higher than 31 of 33 other Gastroesophageal Reflux trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Gastroesophageal Reflux trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00004317 · 600 participants · Phase 4

    Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis

  • NCT00209235 · 600 participants · NA

    Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments

  • NCT01473784 · 600 participants · NA

    Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck

  • NCT01866371 · 600 participants

    High Resolution Retinal Imaging

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00431756, the US trial registry maintained by the National Library of Medicine. NCT00431756 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.